Jean-Baptiste Thibert, Hervé Meinrad, Thibaut Bocquet, Marjolaine Jacques, Thierry Baudonet, Pierre Tiberghien, Sabine Cléophax, Syria Laperche, Pierre Gallian, Sophie Le Cam
{"title":"Paris Olympics and Paralympics: Insights from nationwide coordination in preparedness, supply chain management and blood inventory.","authors":"Jean-Baptiste Thibert, Hervé Meinrad, Thibaut Bocquet, Marjolaine Jacques, Thierry Baudonet, Pierre Tiberghien, Sabine Cléophax, Syria Laperche, Pierre Gallian, Sophie Le Cam","doi":"10.1111/vox.70226","DOIUrl":null,"url":null,"abstract":"<p><p>The Paris 2024 Olympic Games posed a unique challenge due to their scale, associated risks and the need for robust healthcare preparedness. This review outlines the forecasting and anticipatory measures taken by the Etablissement français du sang (EFS) to ensure a resilient blood supply chain throughout the event. A steering committee was formed 2 years in advance to coordinate risk assessments, operational planning and institutional collaboration. The EFS aimed to maintain daily reserves of 90,000 red blood cell (RBC) units, anticipating a 25% shortfall in the Île-de-France region, which was to be balanced by increased contributions from other regions. To support operations, logistical strategies involved the prepositioning of supplies, securing transport routes and reinforcing both trauma centres and Olympic venues. Staffing was also adapted, with changes to work schedules, an extended summer leave period and provisions for remote work at EFS headquarters. In anticipation of seasonal infectious risks, nucleic acid testing (NAT) was implemented for West Nile virus (WNV) and dengue (DENV) in high-risk areas. Cybersecurity measures were also reinforced through strengthened information technology infrastructure and integration with the national cyber crisis response system. These proactive measures proved effective: blood stocks remained stable, only a few arboviral infections were detected and no major cyber incidents occurred. The Paris 2024 experience emphasizes the importance of early, coordinated and cross-sectoral planning in safeguarding national blood supplies during mass events. The centralized structure of the EFS, along with its integration into public health systems and past experience with major events, enabled uninterrupted and resilient service delivery.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1525-1535"},"PeriodicalIF":1.6000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13649366/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70226","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The Paris 2024 Olympic Games posed a unique challenge due to their scale, associated risks and the need for robust healthcare preparedness. This review outlines the forecasting and anticipatory measures taken by the Etablissement français du sang (EFS) to ensure a resilient blood supply chain throughout the event. A steering committee was formed 2 years in advance to coordinate risk assessments, operational planning and institutional collaboration. The EFS aimed to maintain daily reserves of 90,000 red blood cell (RBC) units, anticipating a 25% shortfall in the Île-de-France region, which was to be balanced by increased contributions from other regions. To support operations, logistical strategies involved the prepositioning of supplies, securing transport routes and reinforcing both trauma centres and Olympic venues. Staffing was also adapted, with changes to work schedules, an extended summer leave period and provisions for remote work at EFS headquarters. In anticipation of seasonal infectious risks, nucleic acid testing (NAT) was implemented for West Nile virus (WNV) and dengue (DENV) in high-risk areas. Cybersecurity measures were also reinforced through strengthened information technology infrastructure and integration with the national cyber crisis response system. These proactive measures proved effective: blood stocks remained stable, only a few arboviral infections were detected and no major cyber incidents occurred. The Paris 2024 experience emphasizes the importance of early, coordinated and cross-sectoral planning in safeguarding national blood supplies during mass events. The centralized structure of the EFS, along with its integration into public health systems and past experience with major events, enabled uninterrupted and resilient service delivery.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.